Table 2

Possible molecular targets for therapy in SSc

Target molecules

Available drug name

References

Tyrosine kinases

Imatinib, Nilotinib, Dasatinib

Iwamoto N et al.

Curr Rheumatol Rep.

2011;13:21

SRC kinases

SU6656, Dasatinib

Akhmetshina A et al.

FASEB J.

2008;22:2214

TGF-b inhibitors

Several drugs

Asano Y.

J Dermatol

2010;37:54

Histondeacetylase inhibitor

Trichostatin, SAHA

Huber LC et al.

Arthritis Rheum

2007;56:2755

DNA Methyltransferase inhibitors

5-AZA

Wang Y et al.

Arthritis Rheum

2006;54:2271

Rho associated kinase

Fasudil

Akhmetshina A et al.

Arthritis Rheum

2008;58:2553

Cannabinoid receptor 2 (CB2) agonists

Several drugs

Akhmetshina A et al.

Arthritis Rheum.

2009;60:1129

PPAR γ agonists

None

Wei J et al.

PloS One

2010;5:e13778

Adenosine A2A receptor blockers

None

Chan ES et al.

Arthritis Rheum.

2006;54:2632

IL-13 inhibitors

None

Lafyatis R et al.

Endocr Metab Immune Disord Targets

2006;6:395

Serotonin-Receptor-2B inhibitors

Terguride

Dees C et al.

J Exp Med.

2011; 208:961

CTGF inhibitor

CTGF antibodies

Wang Q et al.

Fibrogenesis Tissue Repair

2011;4:4

IL-6 receptor antagonist

Tocilizmab

Shima Y et al.

Rheumatology(oxford)

2010;49:2408

MicroRNA-29a

None

Maurer B et al.

Arthritis Rheum

2010;62:1733

Fos-Related Antigen-2 (AP-1 family)

None

Reich N et al.

Arthritis Rheum

2010;62:280

Maurer B et al.

Circulation.

2009;120:2367

Iwamoto and Distler Fibrogenesis & Tissue Repair 2012 5(Suppl 1):S19   doi:10.1186/1755-1536-5-S1-S19